Neurocrine Biosciences
NBIX
#1681
Rank
โ‚ฌ11.12 B
Marketcap
110,88ย โ‚ฌ
Share price
2.01%
Change (1 day)
-2.61%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total debt

Total debt on the balance sheet as of December 2025 : โ‚ฌ0.35 Billion

According to Neurocrine Biosciences 's latest financial reports the company's total debt is โ‚ฌ0.35 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Neurocrine Biosciences - Total debt on balance sheet (from 1996 to 2025)

Total debt by year

Year Total debt Change
2025-12-31โ‚ฌ0.35 B-19.16%
2024-12-31โ‚ฌ0.43 B12.85%
2023-12-31โ‚ฌ0.38 B58.12%
2022-12-31โ‚ฌ0.24 B-36.97%
2021-12-31โ‚ฌ0.38 B16.01%
2020-12-31โ‚ฌ0.33 B-24.22%
2019-12-31โ‚ฌ0.44 B30.25%
2018-12-31โ‚ฌ0.33 B10.24%
2017-12-31โ‚ฌ0.30 B
2009-12-31โ‚ฌ8.04 M-26.93%
2008-12-31โ‚ฌ11.01 M982.17%
2007-12-31โ‚ฌ1.01 M-97.5%
2006-12-31โ‚ฌ40.65 M-18.93%
2005-12-31โ‚ฌ50.14 M2.87%
2004-12-31โ‚ฌ48.74 M68.45%
2003-12-31โ‚ฌ28.93 M281.23%
2002-12-31โ‚ฌ7.59 M17.88%
2001-12-31โ‚ฌ6.43 M56.75%
2000-12-31โ‚ฌ4.1 M33.35%
1999-12-31โ‚ฌ3.08 M21.86%
1998-12-31โ‚ฌ2.52 M87.5%
1997-12-31โ‚ฌ1.34 M0%
1996-12-31โ‚ฌ1.34 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Pfizer
PFE
โ‚ฌ51.52 B 14,551.58%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
โ‚ฌ58.20 B 16,452.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
โ‚ฌ35.98 B 10,134.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
โ‚ฌ0.58 B 65.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
โ‚ฌ15.72 M-95.53%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
โ‚ฌ0.52 B 49.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
โ‚ฌ0.11 M-99.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
โ‚ฌ7.57 B 2,055.29%๐Ÿ‡ฌ๐Ÿ‡ง UK